US 11,744,864 B2
Method of treating eye diseases with krill oil
Finn Myhren, Stamsund (NO); Petter-Arnt Hals, Stamsund (NO); Nils Hoem, Stamsund (NO); Andreas Berg Storsve, Stamsund (NO); Papasani V. Subbaiah, Darien, IL (US); Poorna Yalagala, Urbana, IL (US); Sugasini Dhavamani, Urbana, IL (US); and Leon Tai, Urbana, IL (US)
Assigned to THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, Washington, DC (US)
Filed by Aker BioMarine Antarctic AS, Stamsund (NO); and The Board of Trustees of the University of Illinois, Urbana, IL (US)
Filed on Mar. 31, 2021, as Appl. No. 17/218,760.
Claims priority of provisional application 63/113,908, filed on Nov. 15, 2020.
Claims priority of provisional application 63/002,425, filed on Mar. 31, 2020.
Prior Publication US 2021/0308193 A1, Oct. 7, 2021
Int. Cl. A61P 27/02 (2006.01); A61K 9/00 (2006.01); A61K 31/047 (2006.01); A61K 31/122 (2006.01); A61K 31/685 (2006.01); C12P 9/00 (2006.01); A61K 35/612 (2015.01)
CPC A61K 35/612 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/047 (2013.01); A61K 31/122 (2013.01); A61K 31/685 (2013.01); A61P 27/02 (2018.01); C12P 9/00 (2013.01)] 19 Claims
 
1. A method for improving, controlling, reducing, or alleviating one or more symptoms and/or signs of an eye disease or condition in a subject in need thereof comprising:
administering to the subject in need thereof an effective amount of a pharmaceutical or nutraceutical formulation comprising a lysophosphatidylcholine (LPC) composition comprising a LPC-compound selected from the group consisting of any one of formulas 1 to 8, and any combination thereof, so that the symptoms of the disease or condition are improved, controlled, reduced, or alleviated:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein:
R1 is OH or —OC(O)(CH2)nCH3;
R2 is OH or —OC(O)(CH2)nCH3; and
n is 0, 1, or 2;
and wherein the molar ratio of lysoPC-EPA:lysoPC-DHA is in the range of from 1:1 to 5:1; and further wherein
i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA plus the number of moles 2-lysoPC-EPA; and
ii) ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA plus the number of moles 2-lysoPC-DHA.